Navigation Links
Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Date:5/2/2012

urnal of Medicine in December 2010 (n engl j med 363;26).

About XARELTO® (rivaroxaban)
XARELTO® belongs to a group of medicines called anticoagulants, and works by blocking the blood clotting Factor Xa, thereby reducing the tendency to form clots. In the U.S., XARELTO® is indicated to reduce the risk of blood clots in the legs and lungs of people who have just had knee or hip replacement surgery, and to reduce the risk of stroke and other complications related to migrating blood clots in people with atrial fibrillation not caused by a heart valve problem. There is limited information on how XARELTO® compares to a medicine called warfarin in reducing the risk of stroke when the blood levels of warfarin are well-controlled. The blood levels of warfarin often vary in patients.

The extensive program of clinical trials evaluating rivaroxaban makes the compound the most studied oral, Factor Xa inhibitor in the world today. Rivaroxaban is being developed jointly by Janssen Research & Development, LLC and Bayer HealthCare. U.S. marketing rights for XARELTO® are held by Janssen Pharmaceuticals, Inc.

About Janssen Research & Development, LLC
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & Development, LLC and Janssen Pharmaceuticals, Inc., are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit www.janssenrnd.com for more information.

Important Safety Informat
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego
2. Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
3. Record Breaking $327 Million Verdict Upheld in Janssen Case and Request for New Trial Denied
4. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
5. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
6. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
7. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
8. Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research
9. Janssen Products, LP Modifies Prescribing Information for PROCRIT® (Epoetin alfa) in Chronic Kidney Disease
10. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
11. Record Breaking $327 Million Verdict Announced in Janssen Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Calif. , Aug. 27, 2014 Asterias ... U.S. Food and Drug Administration (FDA) to initiate a ... patients with complete cervical spinal cord injury.  The approved ... clinical study of the product, and is designed to ... in patients with complete cervical spinal cord injuries, the ...
(Date:8/26/2014)... Aug. 26, 2014  Kewaunee Scientific Corporation (Nasdaq: ... quarter ended July 31, 2014. Sales for ... $32,003,000 in the first quarter last year. Net earnings ... share, as compared to net earnings of $1,587,000, or ... the prior year. However, both sales and earnings in ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) ... two fidaxomicin Phase 3 trials in patients with ... Meeting of the Infectious Disease Society of America (IDSA) ... investigator Derrick Crook, M.D., of the University of Oxford, ...
... leading home health care and hospice company (Nasdaq: AMED ... home care in this week,s issue of the New England Journal ... Advisory Board. Titled, "Why Health Care is Going ... home care as an increasingly crucial component of America,s health care ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Media Statement From Amedisys on Dr. Steven H. Landers' NEJM Commentary on the Future of Home Care 2
(Date:8/27/2014)... 2014 Top10BestSEOHosting.com compares many popular ... are the most recommended suppliers for webmasters who ... , “GreenGeeks and GoDaddy provide stellar hosting products ... they have managed to provide a wide range ... ease of use that helps diminish the inherent ...
(Date:8/27/2014)... and Ontario, Canada (PRWEB) August 27, 2014 ... through a huge transformation as was revealed in a ... 2014 survey were not just surprising but astonishing as ... survey carried out online interviewed existing members on the ... Facebook. , According to Kaly, 10yeargap marketing department manager," ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Discover Leadership ... personal and corporate transformation through their comprehensive leadership programs. ... Moses has unparalleled experience in the realm of outcome-focused ... this expertise in a new webinar series titled, “A ... Seller.” The first of this two part webinar is ...
(Date:8/27/2014)... NY (PRWEB) August 27, 2014 Overcoming a ... he finally found his niche. The Women’s Radio Network, WRNW1, ... for his continued support and dedication to the WRNW1 family. ... able to have such a positive atmosphere.” After KC Armstrong ... Sirius XM of the Howard Stern show, “Howard 100 News,” ...
(Date:8/27/2014)... 2014 Casey Diekman, assistant professor of ... is helping to gain greater insight into the biological ... Evolution has harmonized the behavior of humans and all ... the cycle of light and dark experienced each day ... hormone production related to natural patterns of sleep/wake behavior ...
Breaking Medicine News(10 mins):Health News:Excellent Hosting Suppliers Recommended By Top10BestSEOHosting.com 2Health News:Survey Reveals Younger Women Dating Older Men 2Health News:Survey Reveals Younger Women Dating Older Men 3Health News:Barb Moses, Vice President of Discover Leadership Training, Announces New Webinar Titled, “A Women’s Guide to Making Her Life Story a Bestseller” 2Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 2Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 3Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 4
... bars are completely interchangeable in the Medifast 5 & ... Medifast, Inc.,(NYSE: MED ), a leading portion-controlled weight-loss ... featuring a great crunchy,taste and a new formula that ... bar flavors include Chocolate Mint Crunch,Peanut Butter Crunch, and ...
... pathway may affect esophageal cancer risk, a dangerous and rapidly ... The University of Texas M. D. Anderson Cancer Center. , ... at the association between variations in genes related to microRNAs ... of Cancer Prevention Research , a journal of the ...
... Health Care recognizes health care ... Award, OAKLAND, Calif., Nov. 5 The California ... the "Director,s,Right Care Initiative Award" for its outstanding work ... presentation of the award and is,part of the DMHC,s ...
... the key factors that health professionals need to be aware ... Researchers from the University of Sheffield, UK, found considerable differences ... 16 viewed a series of sexual scenarios. , "The ... likely to see their partner,s point of view and were ...
... employers cost-effective, turnkey solution,to improve employee health., ... now have a,cost-effective solution to reduce employee ... competitive by attracting and retaining talent. Today,HealthFitness ... - a powerful combination of its eHealth ...
... CITY, China, Nov. 5 /Xinhua-PRNewswire-FirstCall/,-- China Pharma Holdings, ... manufactures, and markets generic and branded,bio-pharmaceutical products in ... 2008 results on Friday, November 7, 2008. In ... at 10:00 a.m. EST on Friday,November 7, 2008 ...
Cached Medicine News:Health News:Medifast Adds New Crunchy Bars to Product Line 2Health News:Gene variations alter risk of esophageal cancer 2Health News:Kaiser Permanente Honored for Success in Diabetes and Heart Disease Prevention 2Health News:Kaiser Permanente Honored for Success in Diabetes and Heart Disease Prevention 3Health News:Kaiser Permanente Honored for Success in Diabetes and Heart Disease Prevention 4Health News:Alcohol advice needs to play a greater role in sex education for teenagers 2Health News:Alcohol advice needs to play a greater role in sex education for teenagers 3Health News:HealthFitness Launches New Preventive Health Solution for Small Employers 2Health News:HealthFitness Launches New Preventive Health Solution for Small Employers 3Health News:China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008 2Health News:China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008 3
Inquire...
... damaged fiber optics reduce the light output to ... in the optical clarity that is so vital. ... essential to prevent further damage and more extensive ... can inspect your cables for you at no ...
Inquire...
... inspects your equipment upon arrival. Our technician then ... provides you with a thorough customer quote. We ... tight budget so well help you prioritize repairs. ... begins., , ISI uses only OEM or widely ...
Medicine Products: